Genome-wide pharmacogenomic analysis of the response to interferon beta therapy in multiple sclerosis.

OBJECTIVE To identify promising candidate genes linked to interindividual differences in the efficacy of interferon beta therapy. Recombinant interferon beta therapy is widely used to reduce disease activity in multiple sclerosis (MS). However, up to 50% of patients continue to have relapses and worsening disability despite therapy. DESIGN We used a genome-wide pharmacogenomic approach to identify single-nucleotide polymorphism (SNP) allelic differences associated with interferon beta therapy response. SETTING Four collaborating centers in the Mediterranean Basin. Data Coordination Center at the University of California, San Francisco. PATIENTS A cohort of 206 patients with relapsing-remitting MS followed up prospectively for 2 years after initiation of treatment. INTERVENTION DNA was pooled and hybridized to Affymetrix 100K GeneChips. Pooling schemes were designed to minimize confounding batch effects and increase confidence by technical replication. MAIN OUTCOME MEASURES Single-nucleotide polymorphism detection. Comparison of allelic frequencies between good responders and nonresponders to interferon beta therapy. RESULTS A multianalytical approach detected significant associations between several SNPs and treatment response, which were validated by individual DNA genotyping on an independent platform. After the validation stage was complete, 81 additional individuals were added to the analysis to increase power. We found that responders and nonresponders had significantly different genotype frequencies for SNPs located in many genes, including glypican 5, collagen type XXV alpha1, hyaluronan proteoglycan link protein, calpastatin, and neuronal PAS domain protein 3. CONCLUSIONS The reported results address the question of genetic heterogeneity in MS and the response to immunotherapy by analysis of the correlation between different genotypes and clinical response to interferon beta therapy. Many of the detected differences between responders and nonresponders were genes associated with ion channels and signal transduction pathways. The study also suggests that genetic variants in heparan sulfate proteoglycan genes may be of clinical interest in MS as predictors of the response to therapy. In addition to new insights into the mechanistic biology of interferon beta, these results help define the molecular basis of interferon beta therapy response heterogeneity.

[1]  D. Carey,et al.  Glypican-1 and α4(V) Collagen Are Required for Schwann Cell Myelination , 2006, The Journal of Neuroscience.

[2]  D. Goodin,et al.  Neutralizing antibodies to interferon beta: Assessment of their clinical and radiographic impact: An evidence report: [RETIRED] , 2007, Neurology.

[3]  P. Sham,et al.  SNPs, microarrays and pooled DNA: identification of four loci associated with mild mental impairment in a sample of 6000 children. , 2005, Human molecular genetics.

[4]  Xiaoquan Wen,et al.  Coverage and Characteristics of the Affymetrix GeneChip Human Mapping 100K SNP Set , 2006, PLoS genetics.

[5]  C. Mayorga,et al.  HLA class II and response to interferon‐beta in multiple sclerosis , 2005, Acta neurologica Scandinavica.

[6]  R. Rudick,et al.  Extended observations on MS patients treated with IM interferon-β1a (Avonex™): implications for modern MS trials and therapeutics , 2000, Journal of Neuroimmunology.

[7]  X. Montalban,et al.  Pharmacogenomic analysis of interferon receptor polymorphisms in multiple sclerosis , 2003, Genes and Immunity.

[8]  Hong-Guang Xie,et al.  Gene variants in noncoding regions and their possible consequences. , 2006, Pharmacogenomics.

[9]  Fuencisla Matesanz,et al.  IFNAR1 and IFNAR2 polymorphisms confer susceptibility to multiple sclerosis but not to interferon-beta treatment response , 2005, Journal of Neuroimmunology.

[10]  P. Bartold,et al.  Growth factors and cytokines modulate gene expression of cell‐surface proteoglycans in human periodontal ligament cells , 2001, Journal of cellular physiology.

[11]  D. Silberberg,et al.  New diagnostic criteria for multiple sclerosis: Guidelines for research protocols , 1983, Annals of neurology.

[12]  X. Montalban,et al.  Defining the response to interferon‐β in relapsing‐remitting multiple sclerosis patients , 2006, Annals of neurology.

[13]  J. Uhm,et al.  Interferon β‐1b decreases the migration of T lymphocytes in vitro: Effects on matrix metalloproteinase‐9 , 1996 .

[14]  Y. Benjamini,et al.  More powerful procedures for multiple significance testing. , 1990, Statistics in medicine.

[15]  T. Speed,et al.  GOstat: find statistically overrepresented Gene Ontologies within a group of genes. , 2004, Bioinformatics.

[16]  Pierre J. Vinken,et al.  Multiple Sclerosis and Other Demyelinating Diseases , 1970 .

[17]  Pablo Villoslada,et al.  European Population Substructure: Clustering of Northern and Southern Populations , 2006, PLoS genetics.

[18]  E. Waubant,et al.  Interferon beta‐1b inhibits gelatinase secretion and in vitro migration of human T cells: A possible mechanism for treatment efficacy in multiple sclerosis , 1996, Annals of neurology.

[19]  Dennis P Wall,et al.  Heparan sulfate proteoglycans and the emergence of neuronal connectivity , 2006, Current Opinion in Neurobiology.

[20]  D. Carey,et al.  Glypican-1 and alpha4(V) collagen are required for Schwann cell myelination. , 2006, Journal of Neuroscience.

[21]  G. Salemi,et al.  Multiple Sclerosis Severity Score: Using disability and disease duration to rate disease severity , 2005, Neurology.

[22]  C. Chien,et al.  When sugars guide axons: insights from heparan sulphate proteoglycan mutants , 2004, Nature Reviews Genetics.

[23]  J. Uhm,et al.  Interferon beta-1b decreases the migration of T lymphocytes in vitro: effects on matrix metalloproteinase-9. , 1996, Annals of neurology.

[24]  A. Pachner.  Neutralizing antibodies to interferon beta: Assessment of their clinical and radiographic impact: An evidence report: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology , 2007, Neurology.

[25]  C. Granger,et al.  Intramuscular interferon beta‐1a for disease progression in relapsing multiple sclerosis , 1996, Annals of neurology.

[26]  M. O’Donovan,et al.  DNA Pooling: a tool for large-scale association studies , 2002, Nature Reviews Genetics.

[27]  E. Urcelay,et al.  An IFNG polymorphism is associated with interferon-beta response in Spanish MS patients , 2006, Journal of Neuroimmunology.

[28]  G. Abecasis,et al.  Joint analysis is more efficient than replication-based analysis for two-stage genome-wide association studies , 2006, Nature Genetics.

[29]  Michael Hutchinson,et al.  Pharmacogenomics of responsiveness to interferon IFN‐β treatment in multiple sclerosis: A genetic screen of 100 type I interferon‐inducible genes , 2005, Clinical pharmacology and therapeutics.

[30]  P. Duquette,et al.  Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group. , 1993 .